Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations

[1]  Jae Cheol Lee,et al.  Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer , 2021, Scientific Reports.

[2]  S. Ou,et al.  Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. , 2021, Lung cancer.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Y. Ohe,et al.  Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression , 2020, Clinical Cancer Research.

[5]  A. Neri,et al.  Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? , 2020, Frontiers in Oncology.

[6]  M. Ahn,et al.  Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L. , 2020 .

[7]  Anna L. Brown,et al.  Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer , 2020, Cell reports medicine.

[8]  L. Landi,et al.  Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs , 2020, Journal of clinical medicine.

[9]  H. Hou,et al.  Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis , 2019, BMC Cancer.

[10]  Olaf Neumann,et al.  Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases , 2019, International journal of cancer.

[11]  C. Couture,et al.  Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes , 2019, Molecular Cancer Therapeutics.

[12]  A. Stenzinger,et al.  Defining molecular risk in ALK+ NSCLC , 2019, Oncotarget.

[13]  L. Moens,et al.  Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. , 2019, Lung cancer.

[14]  Fanshuang Zhang,et al.  Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer , 2019, Cancer medicine.

[15]  Jiamei Li,et al.  Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer , 2019, Oncology letters.

[16]  J. Ahn,et al.  Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR‐Mutated Advanced NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  P. Schirmacher,et al.  Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival , 2019, Cancers.

[18]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[19]  F. Ciardiello,et al.  Role and targeting of anaplastic lymphoma kinase in cancer , 2018, Molecular Cancer.

[20]  Jon R. Armstrong,et al.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer , 2018, Modern Pathology.

[21]  Wei Wu,et al.  Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer , 2017, Cancers.

[22]  X. Yi,et al.  TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. , 2018, Journal of thoracic disease.

[23]  M. Tsao,et al.  Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). , 2017, Lung cancer.

[24]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[25]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[26]  A. Shaw,et al.  Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.

[27]  Jeffrey N Myers,et al.  TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response , 2016, Journal of cellular biochemistry.

[28]  T. Clackson,et al.  Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[29]  Weijun Ou,et al.  TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis , 2016, Molecular and clinical oncology.

[30]  Michael Thomas,et al.  Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial , 2016, The Lancet. Oncology.

[31]  R. Govindan,et al.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  V. Mittal,et al.  Novel ALK inhibitors in clinical use and development , 2015, Journal of Hematology & Oncology.

[33]  Hyojin Kim,et al.  Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. , 2015, Translational lung cancer research.

[34]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[35]  R. Govindan,et al.  TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal , 2014, Clinical Cancer Research.

[36]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[37]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[38]  Jianmin Wu,et al.  Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.

[39]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[40]  F. Végran,et al.  Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma , 2013, PloS one.

[41]  Ming K. Lee,et al.  Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. , 2012, Cancer cell.

[42]  A. Wellstein,et al.  Hunting ALK to feed targeted cancer therapy , 2011, Nature Medicine.

[43]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[44]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[45]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[46]  Anindita Das,et al.  Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes , 2004, Oncogene.

[47]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[48]  Xue Wu,et al.  Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. , 2019, Lung cancer.

[49]  D. Lane,et al.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others , 2018, Nature Reviews Clinical Oncology.

[50]  M. Visker,et al.  Cell-Type - , 2017 .

[51]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[52]  R. Rosell,et al.  Nondisruptive p 53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non – Small Cell Lung Cancer , 2014 .

[53]  M. Scian,et al.  Tumor-derived p53 mutants induce NF-kappaB2 gene expression. , 2005, Molecular and cellular biology.